Economic analysis of unrelated allogeneic bone marrow transplantation:: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease

被引:11
作者
de Lissovoy, G
Hurd, D
Carter, S
Beatty, P
Ewell, M
Henslee-Downey, J
Kernan, N
Yanovich, S
Weisdorf, D
机构
[1] MEDTAP Int Inc, Ctr Hlth Econ, Bethesda, MD 20814 USA
[2] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA
[3] EMMES Corp, Rockville, MD USA
[4] Univ Utah, Med Ctr, Salt Lake City, UT USA
[5] Univ S Carolina, Div Transplantat Med, Columbia, SC 29208 USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[7] Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA
[8] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA
关键词
cost-effectiveness; economics; T-cell depletion;
D O I
10.1038/sj.bmt.1705078
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
Unrelated-donor marrow transplantation is a potential option for transplant candidates lacking a compatible related donor. The T-cell Depletion Study compared the 3-year disease-free survival for patients receiving T-cell-depleted ( TCD) donor marrow (n = 203) vs unmanipulated donor marrow with methotrexate and cyclosporine (M/C) ( n 207). Hospital costs during index admission were documented with billing data, while hospital costs during subsequent 6-month follow-up were estimated from case report forms. Patients with index admission billing were included in the analysis ( TCD 119, M/C 127). Total hospital length of stay (LOS) was similar across groups, with medians 47.0 days for TCD and 52.0 days for M/C (P = 0.72). Total hospital costs were comparable, $145115 vs $141981 (P = 0.63) for TCD and M/C, respectively. However, controlling for site and patient characteristics, TCD was associated with a 12.1% reduction in LOS for the index admission (95% CI - 19.4%, - 4.3%). Independent of treatment, HLA matching (6/6) was associated with an 8.6% ( 95% CI - 17.4%, + 1.2%) reduction in the index admission LOS, while cost was lower by 15.8% ( 95% CI - 26.7%, - 3.3%). Treatment costs were similar for TCD and M/C study groups. Savings on reduced cost for treating acute graft-versus-host disease were likely offset by increase in serious infections in the TCD arm.
引用
收藏
页码:539 / 546
页数:8
相关论文
共 15 条
[1]
ALTMAIER EM, UNPUB EFFECT UNRELAT
[2]
Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation [J].
Bennett, CL ;
Waters, TM ;
Stinson, TJ ;
Almagor, O ;
Pavletic, ZS ;
Tarantolo, SR ;
Bishop, MR .
BONE MARROW TRANSPLANTATION, 1999, 24 (05) :555-560
[3]
ECONOMIC-ANALYSIS AND CLINICAL-TRIALS [J].
DRUMMOND, MF ;
STODDART, GL .
CONTROLLED CLINICAL TRIALS, 1984, 5 (02) :115-128
[4]
GARBER AM, 1996, COST EFFECTIVENESS H, P28
[5]
A detailed analysis of charges for hematopoietic stem cell transplantation at a children's hospital [J].
Kline, RM ;
Meiman, S ;
Tarantino, MD ;
Herzig, RH ;
Bertolone, SJ .
BONE MARROW TRANSPLANTATION, 1998, 21 (02) :195-203
[6]
The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia [J].
Lee, SJ ;
Anasetti, C ;
Kuntz, KM ;
Patten, J ;
Antin, JH ;
Weeks, JC .
BLOOD, 1998, 92 (11) :4047-4052
[7]
Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs [J].
Lee, SJ ;
Zahrieh, D ;
Alyea, EP ;
Weller, E ;
Ho, VT ;
Antin, JH ;
Soiffer, RJ .
BLOOD, 2002, 100 (08) :2697-2702
[8]
Estimating log models: to transform or not to transform? [J].
Manning, WG ;
Mullahy, J .
JOURNAL OF HEALTH ECONOMICS, 2001, 20 (04) :461-494
[9]
Importance of hospital volume in the overall management of pancreatic cancer [J].
Sosa, JA ;
Bowman, HM ;
Gordon, TA ;
Bass, EB ;
Yeo, CJ ;
Lillemoe, KD ;
Pitt, HA ;
Tielsch, JM ;
Cameron, JL .
ANNALS OF SURGERY, 1998, 228 (03) :429-436
[10]
Steiner Claudia, 2002, Eff Clin Pract, V5, P143